Recombinant Coagulation Factor Concentrate Market

Coagulation factor is the main drug for the treatment of hemophilia, and it has experienced the evolution and development from the first generation blood-derived coagulation factor products to the second generation recombinant products and the third generation long-acting recombinant products. Recombinant coagulation factors avoid the possibility of human infection and get rid of the dependence on plasma; long-acting products improve patient compliance and treatment convenience by prolonging the half-life of drugs, and long-acting recombinant coagulation factors are the trend of future research and development.
Recombinant Coagulation Factor Concentrate Market contains market size and forecasts of Recombinant Coagulation Factor Concentrate in global, including the following market information:
Global Recombinant Coagulation Factor Concentrate Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Recombinant Coagulation Factor Concentrate Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Recombinant Coagulation Factor Concentrate companies in 2021 (%)
The global Recombinant Coagulation Factor Concentrate market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
250 IU Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Recombinant Coagulation Factor Concentrate include Bayer, Alprolix, Benefix, Idelvion, Lxinity, Rebinyn, Rixubis, CSL and Baxalta, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Recombinant Coagulation Factor Concentrate manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Coagulation Factor Concentrate Market, by Dose, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Coagulation Factor Concentrate Market Segment Percentages, by Dose, 2021 (%)
250 IU
500 IU
1000 IU
2000 IU
Global Recombinant Coagulation Factor Concentrate Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Coagulation Factor Concentrate Market Segment Percentages, by Application, 2021 (%)
Hopistial
Clinic
Others
Global Recombinant Coagulation Factor Concentrate Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Coagulation Factor Concentrate Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Coagulation Factor Concentrate revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Recombinant Coagulation Factor Concentrate revenues share in global market, 2021 (%)
Key companies Recombinant Coagulation Factor Concentrate sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Recombinant Coagulation Factor Concentrate sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
Alprolix
Benefix
Idelvion
Lxinity
Rebinyn
Rixubis
CSL
Baxalta
Sanofi
Biogen
Pfizer
Novo Disk
Baxter
Wyeth
??????????????
????
????
????
???????????????